Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL510 1.5 mg versus 3.0 mg versus placebo for insomnia in elderly subjects
ISRCTN82088636Phase 2Completed
- Sponsor
- Alliance Pharma
- Start
- Jul 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of APL510 in Insomnia (3 arms), sponsored by Alliance Pharma. Primary endpoint: Total sleep time. Started Jul 2005; status: completed.
02
Drugs
APL510
03
Conditions
Insomnia
Beyond the preview
Go deeper on ISRCTN82088636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN82088636.